Dyadic International Inc., DE
DYAI
Get informed when a big investor buys or sells
+ FollowMarket Cap$28.5M
Close$
$-0.37
151.1% downside
Current Fair Value
151.1% downsideOvervalued by 151.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $28.50 Million |
|---|---|
| Enterprise Value | $29.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.23 |
| Beta | 1.16 |
| Outstanding Shares | 36,397,997 |
Return
| Return on Equity | 1788.36% |
|---|---|
| Return on Assets | -93.37% |
| Return on Invested Capital | -155.51% |
Valuation & Multiples
| P/E Ratio | -3.67 |
|---|---|
| PEG | 102.17 |
| Price to Sales | - |
| Price to Book Ratio | -0.73 |
| Enterprise Value to Revenue | 6.53 |
| Enterprise Value to EBIT | -4.1 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | -15.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$903,750
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$1.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 72,900▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 15.76%▼ 0.39% |
|---|---|
| Total Invested | $4.22M▼ 19.50% |
| Investors Holding | 37▼ 1.00% |
ESG Score
No data
About Dyadic International Inc., DE
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly ...